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Introduction 
Amoebiasis, which is caused by the intestinal 
protozoan  Entamoeba histolytica, is a ubiquitous 
parasitic infection affecting approximately 10% of 
the world’s population and causing more deaths 
every year (100,000 deaths) than any other 
parasitic infection, with the exception of malaria 
and schistosomiasis [1–3]. Most individuals with 
an  E.  histolytica  infection are asymptomatic, but 
some develop severe invasive disease, such as 
amoebic colitis. Other manifestations, such as 
pulmonary, cardiac or brain involvement, are rare. 
Intestinal amoebiasis can probably also present as 
a chronic, non-dysenteric syndrome of diarrhoea, 
weight loss, and abdominal pain that can last for 
years and mimic inflammatory bowel disease. 
Fulminant colitis with bowel necrosis leading to 
perforation and peritonitis occurs in only about 
0.5% of cases, but it is associated with a mortality 
rate of more than 40%. Patients with invasive 
amoebiasis living in the United Kingdom and other 
developed countries generally acquire the infection 
in another country in which the pathogenic species 
is endemic. Areas that have high rates of amoebic 
infection include India, Africa, Mexico and parts of 
Central and South America. Infection with 
pathogenic E. histolytica is not a common cause of 
travelers’ diarrhoea, and gastrointestinal infection 
is uncommon in travelers who have spent less 
than one month in endemic areas. 
Despite the availability of sophisticated 
investigative procedures, differentiating invasive 
colonic amoebiasis from idiopathic inflammatory 
bowel disease (IBD) may be difficult. This case is 
presented to remind clinicians of the similarities in 
the clinical presentation and endoscopic features 
of these two conditions, and to highlight the 
difficulty in differentiating them. 
 
Case report 
We present the case of a 68-year-old woman 
who was diagnosed with ulcerative colitis (UC) 
in1983. Since then she had frequent flare-ups and 
was repeatedly treated with courses of steroids. 
She was receiving 5-amino salicylic acid as a 
maintenance therapy. She presented to the clinic 
with a flare-up that coincided with her return from 
Thailand 22 days earlier. She complained of 
passing 7-8 loose motions per day and having 
generalised symptoms of malaise, low grade fever 
and tachycardia. With these symptoms and a C-
reactive protein (CRP) of 55, she was hospitalised 
and placed on intravenous steroids. Stool samples 
were negative by both microscopy and culture. 
Despite intravenous steroids, her diarrhoea 
worsened and became bloody. Sigmoidoscopy 
showed severe inflammation with cobblestone 
formation, bleeding, and friability of the mucosa 
from the rectum to beyond the sigmoid colon, 
which is not characteristic of UC. Therefore, 
multiple biopsies were taken from the rectum and 
sigmoid colon; the histology showed focal mucosal 
ulceration due to invasive amoebiasis, and E. 
histolytica parasites were evident (Fig. 2). Steroids 
were stopped and the patient was started on a 
course of metronidazole at 750 mg three times 
daily for 10 days, followed by oral diloxanide 
furoate (500 mg)   three times a day  for 10 days. 
She eventually recovered and was discharged on 
5-amino salicylic acid.  Since then she has 
remained in complete remission.  
 
Discussion  
Amoebic colitis is a disease with diverse clinical 
manifestations that frequently lead to confusing it 
with other types of colitis. When misdiagnosed as 
UC, undesirable outcomes might occur from the 
use of steroids, including colectomy or even 
death. Clinicians must keep amoebiasis in mind in 
the differential diagnosis of patients suspected of 
having UC or Crohn’s disease [3]. A recent study 
in Turkey showed that amoeba infection in 
patients with IBD, especially those with UC, is 
more prevalent than in the normal population [4]. 
With more frequent air travel, amoebic colitis is an 
important “not to miss” diagnosis even in the 
developed world. However, it should be noted that 
amoebiasis can be contracted by people, 
especially children, who have never been abroad. 
Stool microscopy is a relatively poor method for 
diagnosing intestinal amoebiasis because it is 
time-consuming, laborious, and requires specific 
expertise. Culture methods are often unrewarding, 
with a sensitivity of only about 50%. However, 
monoclonal antibodies that specifically recognise 
pathogenic  E.  histolytica  strains but not 
nonpathogenic E. dispar in faeces and serum are 
commercially available. Antigen detection kits 
using enzyme-linked immunosorbent assay 
(ELISA), radioimmunoassay, or 
immunofluorescence have been developed. 
Serology is also useful for diagnosing amoebiasis. 
Infection with E.  histolytica  results in the 
development of antibodies, whereas E. dispar 
infection does not. Antibodies will usually be 
detectable within five to seven days of acute 
infection and may persist for years. Up to 25% of 
uninfected individuals in endemic areas have anti-
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amoebic antibodies due to previous, often 
undiagnosed infection with E. histolytica.  
Sigmoidoscopy and/or colonoscopy can be 
performed either to diagnose amoebiasis or to 
exclude other causes of the patients’ symptoms. 
Microscopy may reveal cysts or trophozoites in 
scrapings or biopsies, which are best taken from 
the edge of ulcers. Colonic lesions in amoebic 
dysentery range from nonspecific mucosal 
thickening and inflammation to classic flask-
shaped amoebic ulcers. However, colonoscopy is 
not recommended as a routine diagnostic 
approach because intestinal amoebic ulcerations 
increase the likelihood of perforation during 
instillation of air to expand the colon. 
Asymptomatic carriers of E. histolytica should be 
treated with a luminal agent to minimise the 
spread of disease and the risk of developing 
invasive disease. Recommended drugs for 
treatment of symptomatic intestinal disease and 
for hepatic abscess are metronidazole and 
tinidazole. These drugs may not eliminate the 
intraluminal cysts, and so they should be 
immediately followed by treatment with iodoquinol, 
paromomycin, or diloxanide furoate. 
 
 
Figure 1: Numerous E. histolytica trophozoites at the 
base of ulcerated colonic tissue stained with 
hematoxylin-eosin. 
 
Conclusion 
E.  histolytica  continues to be an important, 
worldwide source of disease. It is the primary 
cause of amoebic dysentery in developing 
countries. Amoebic colitis needs to be kept in mind 
in the differential diagnosis of inflammatory bowel 
disease, particularly in high-risk individuals. Early 
diagnosis and treatment with metronidazole or 
tinidazole should be instituted once acute amoebic 
colitis is suspected. We believe that the remission 
of the case presented was due to treatment of the 
amoeba infection. We suggest that amoebiasis 
should be sought and treated in every patient with 
ulcerative colitis. 
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